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Skeletal muscle development is orchestrated by the myogenic regulatory factor MyoD, whose activity is blocked in myoblasts by
proteins preventing its nuclear translocation and/or binding to G/C-centered E-boxes in target genes. Recent evidence indicates
that muscle gene expression is also regulated at the cis level by differential affinity for DNA betweenMyoD and other E-box
binding proteins during myogenesis. MyoD binds to G/C-centered E-boxes, enriched in muscle differentiation genes, in myo-
tubes but not in myoblasts. Here, we used cell-based and in vivo Drosophila, Xenopus laevis, and mouse models to show that
ZEB1, a G/C-centered E-box binding transcriptional repressor, imposes a temporary stage-dependent inhibition of muscle gene
expression and differentiation via CtBP-mediated transcriptional repression.We found that, contrary toMyoD, ZEB1 binds to
G/C-centered E-boxes in muscle differentiation genes at the myoblast stage but not in myotubes. Its knockdown results in preco-
cious expression of muscle differentiation genes and acceleration of myotube formation. Inhibition of muscle genes by ZEB1
occurs via transcriptional repression and involves recruitment of the CtBP corepressor. Lastly, we show that the pattern of gene
expression associated with muscle differentiation is accelerated in ZEB1/mouse embryos. These results set ZEB1 as an impor-
tant regulator of the temporal pattern of gene expression controlling muscle differentiation.
Muscle gene expression is orchestrated by a small set of myo-genic regulatory factors (MRFs), namely, Myf-5, MyoD,
myogenin, and MRF4, that bind to E-box sequences (CANNTG)
in the regulatory regions of target genes by forming homodimers
with themselves or heterodimers with E proteins (reviewed in ref-
erences 1 and 2). During myogenesis, there is a division of labor
among MRFs, with Myf-5 and MyoD determining lineage com-
mitment and myogenin driving terminal differentiation of myo-
blasts into myotubes (1). In addition, there is also a regulatory
interplay among MRFs, as Myf5 and MyoD induce myogenin,
which in turn regulates MRF4, while MyoD and myogenin can
activate their own expression. Overexpression of MRFs in non-
muscle cells (e.g., fibroblasts) is sufficient to induce a number of
muscle markers and, to different degrees, drive a myogenic differ-
entiation program (3–5).
However, MRFs cannot explain by themselves the sophisti-
cated pattern of temporal and spatial gene expression duringmyo-
genesis. Determination and terminal differentiation of skeletal
muscle precursors require the concerted action of MRFs with
many other proteins, whichmodulate the expression, intracellular
localization, and/or transcriptional activity of MRFs (1, 6). For
instance, in myoblasts, MyoD does not induce downstream mus-
cle differentiation target genes, as its function is temporarily
blocked through multiple mechanisms. Inter alia, the interaction
of MyoD (and/or its E protein partners) with a number of factors
prevents MyoD from entering the nucleus (e.g., interaction of
MyoDwith I-mfa/MDFI), from binding to DNA (e.g., with Twist,
Id, and Mist-1), and/or from activating its targets (e.g., with
Mist-1 and MyoR) (7–11). However, these negative regulatory
factors are still not sufficient to account for the differential gene
expression signature in myoblasts and myotubes (1, 2, 6).
Recent works have revealed that, independently of their
squelching by proteins like Twist or Id, binding of MRFs to DNA
during muscle differentiation is also controlled at the cis level.
Differential affinity of MyoD vis-à-vis other E-box binding pro-
teins for E-box sequences dictates their occupancy in myoblasts
and myotubes (12, 13). Binding of MyoD to MyoD-specific E-
boxes promotes transcriptional activation of muscle differentia-
tion genesmuchmore strongly than doesMyoD binding to E-box
sequences that are also shared with NeuroD2, another basic helix-
loop-helix (bHLH) protein that regulates neuronal differentiation
(12). In addition, E-box sequence specificity, e.g., G/C versus A/T
as central nucleotides, determines DNAoccupancy duringmuscle
differentiation (13). In myoblasts, MyoD binds to A/T-centered
E-boxes in genes associated with cell proliferation but does not
interact with G/C-centered E-boxes that are enriched in the regu-
latory regions of muscle differentiation genes (13). The latter E-
boxes are occupied during the myoblast stage by transcriptional
repressors of the Snail family (13). As differentiation progresses,
Snail factors are displaced from these E-boxes by MyoD, thus
inducing the expression of amuscle differentiation gene signature
(13).
Another transcriptional repressor that specifically recognizes
G/C-centered E-boxes is ZEB1 (also known as EF1) (reviewed in
references 14 and 15). Like Snail factors, ZEB1 is best known for its
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role in cancer progression, where it triggers an epithelial-to-mes-
enchymal transition (EMT), endowing cancer cells with a proin-
vasive phenotype (14, 15). ZEB1 is expressed in the epithelium of
the undifferentiated somite and in the dermomyotome during
mouse and chick embryogenesis (16, 17). Mutation and overex-
pression of its ortholog inDrosophila melanogaster, zfh-1, leads to
altered somatic musculature formation (18, 19). Interestingly,
ZEB1 is a downstream target of both MyoD and Snail factors
(20–23). In in vitro overexpression experiments, ZEB1 competes
with bHLH and Snail factors for binding to E-boxes in different
genes (e.g., those for immunoglobulin heavy chain enhancer, 4
integrin promoter, CD4 proximal enhancer/promoter, and p73
promoter/intron 1) (24–28).
This pattern of ZEB1 expression during development and its
exclusive affinity for G/C-centered E-boxes prompted us to ques-
tion whether endogenous ZEB1 is regulating muscle gene expres-
sion. Using a number of cell-based and in vivo models, we show
here that ZEB1 imposes a temporary stage-dependent inhibition
of muscle gene expression and differentiation via CtBP-mediated
transcriptional repression. ZEB1 knockdown triggers early pro-
tein andmRNA expression ofmuscle determination and differen-
tiation genes and, accordingly, precocious myotube conversion.
In a reverse pattern with respect to MyoD, ZEB1 binds to G/C-
centered E-boxes in muscle differentiation genes at the myoblast
stage but not inmyotubes. Negative regulation ofmuscle genes by
ZEB1 in myoblasts occurs via transcriptional repression. In both
cell-based systems andXenopus laevis andDrosophila embryos, we
show that this repression involves an interaction of ZEB1 with
the CtBP corepressor. Finally, we found that the temporal pat-
tern of muscle differentiation gene expression is accelerated in
ZEB1/ mouse embryos. Together, these results indicate that
endogenousZEB1plays an important role regulating the temporal
pattern of gene expression during muscle differentiation.
MATERIALS AND METHODS
Cells, cell culture, and transfections. C2C12 and C3H-10T1/2 cells were
obtained from the American Tissue Culture Collection andmaintained in
Dulbecco’s modified Eagle’s medium (DMEM) (Lonza) supplemented
with 12% fetal bovine serum (FBS) (Sigma). Cells were transiently trans-
fected with expression or reporter vectors by using Lipofectamine 2000
(Life Technologies) and/or with small interfering RNA (siRNA) oligonu-
cleotides by using Lipofectamine RNAiMAX (Life Technologies) accord-
ing to the manufacturer’s instructions.
Antibodies. The following commercial antibodies were used in this
work: ZEB1 (H-102; Santa Cruz Biotechnology [SCBT]), sarcomeric
pan-myosin (MF-20; Development Studies Hybridoma Bank
[DSHB]), myosin heavy chain IIa (MyH2) (SC-71; DSHB), myosin
heavy chain IIb (MyH4) (BF-F3; DSHB), MyoD (C-20; SCBT), myo-
genin (F5D; BD Pharmingen), CtBP1/2 (E-12; SCBT), and -tubulin
(B5-1-2; Sigma) antibodies. Antibodies against Drosophila muscle
markers were obtained as follows: mouse anti-myosin heavy chain
(anti-MHC) antibody was a gift from D. Kiehart (Duke University),
and rabbit anti-MEF2 antibody was a gift from B. M. Patterson (Na-
tional Cancer Institute, NIH). Secondary horseradish peroxidase
(HRP)-conjugated donkey anti-mouse IgG and goat anti-rabbit IgG
antibodies were purchased from Jackson ImmunoResearch (JIR). For
blocking in immunostaining assays, normal serum from the host spe-
cies of the secondary antibody was purchased from JIR. As an IgG
control for chromatin immunoprecipitation (ChIP) assays, normal
rabbit IgG and normal goat IgG-containing serum were purchased
from SCBT and JIR, respectively.
RNA interference. The three set of siRNAs used in this study to target
mouse ZEB1 originated as follows. The siRNA duplex referred to as
si1ZEB1, with the sense sequence 5=-GACCAGAACAGUGUUCCAUGU
UUAA-3=, was purchased from Life Technologies as a Select RNAi siRNA
(MSS210696) guaranteed to have no off-target effects. si2ZEB1 (sense
sequence 5=-AACUGAACCUGUGGAUUAU-3=) was described previ-
ously (29). Finally, the siRNA referred to as si3ZEB1 was purchased from
SCBT (catalog number sc-38644) and consisted of a pool of three different
siRNA duplexes of the following sense sequences: 5=-GAAGAACCCUUG
AACUUGU-3=, 5=-GAACAGUGUUCCAUGUUUA-3=, and 5=-CAACC
AUGAAGGAUCUAUA-3=. As negative controls in interference experi-
ments, the following siRNAs were used: 5=-UAUAGCUUAGUUCGUAA
CC-3= and Select RNAi siRNA LO GC (catalog no. 12935-200; Life
Technologies). In Western blot and quantitative real-time PCR (qRT-
PCR) studies, an additional control siRNA targeting firefly luciferase (5=-
GAUUAUGUCCGGUUAUGUA-3=) (30) was also used. The siRNA du-
plex against CtBP1/2 with the sense sequence 5=-GAACUGTGUCAACA
AGGAC-3= was previously described (31).
Plasmids.Expression vectors used in the studywere obtained from the
following researchers: full-length mouse ZEB1 was obtained from M.
Saito (Tokyo University, Japan) (32), full-length mouse ZEB1 with mu-
tated CtBP binding sites was obtained from Y. Higashi (Institute for De-
velopmental Research, Kasugai, Japan) (33), and pEMSV-MyoD was
from the late H. Weintraub (Fred Hutchinson Cancer Research Center,
Seattle,WA) (3). TheXenopusMyoDconstruct, containing the full-length
cDNA plus the 5= and 3= untranslated regions and cloned into pSP64T,
was obtained from J. Gurdon (Gurdon Institute, Cambridge, United
Kingdom). Simian virus 40 (SV40)–-galactosidase (-gal) was pur-
chased from Promega, pcDNA3 was purchased from Invitrogen, and the
pBluescript SK vector was purchased from Stratagene-Agilent. Firefly lu-
ciferase reporters for the promoters used in this article were provided by
the following researchers: 5.5 kb of rat -MHC promoter was obtained
fromE.N.Olson (University of Texas Southwestern,Dallas, TX), (34), 2.3
kb of quail troponin I was obtained from S. Konieczny (Purdue Univer-
sity, West Lafayette, IN) (35), a bp1256 mouse muscle creatine kinase
(MCK) promoter was obtained from S. A. Leibovitch (INRA, Montpel-
lier, France) (36), and a 4-kb enhancer plus a 2.7-kb promoter of the
humanMyoD gene were obtained from J. P. Capone (McMaster Univer-
sity, Hamilton, ON, Canada) (37).
Western blots.Western blot assays were performed as described pre-
viously (38). Briefly, cells were lysed in radioimmunoprecipitation assay
(RIPA) buffer (150 mMNaCl, 1%NP-40, 0.5% SDS, 50 mMTris [pH 8],
2 mM EDTA, plus protease inhibitors) and loaded onto polyacrylamide
gels. Gels were then transferred onto a polyvinylidene difluoride (PVDF)
membrane (Immobilon-P; Millipore). Following blocking for nonspe-
cific antibody binding with 5% nonfat milk, membranes were incubated
with the corresponding primary andHRP-conjugated secondary antibod-
ies before the reaction was developed by using the Pierce ECL Western
blotting substrate or SuperSignal West Pico chemiluminescent substrate
(Thermo Fisher Scientific). Western blots shown in this study are repre-
sentative of at least four independent experiments.
Myogenic conversion assays. For differentiation of C2C12myoblasts
into myotubes, cells were seeded into 6-well plates and grown in growth
medium (GM) (DMEM plus 20% FBS) until they reached 80 to 90%
confluence, at which time the GM was switched to differentiation me-
dium (DM) (DMEM supplemented with 2% horse serum; Sigma) and
maintained in DM for different periods. In selected experiments as spe-
cifically indicated, cells were maintained in GM even after reaching full
confluence. Cells were fixed in20°C-chilledmethanol and blocked with
2% gelatin (from cold-water fish skin; Sigma) before being stained
with pan-myosin antibody MF-20 for 2 h, washed with phosphate-
buffered saline (PBS), incubated with HRP-conjugated anti-mouse
IgG antibody (JIR), and developed with a 3,3=-diaminobenzidine
(DAB) substrate kit (Vector Laboratories). Finally, cells were incu-
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bated for 30 s with hematoxylin for nucleus counterstaining and
washed with PBS.
RNA extraction and quantitative real-time PCR. Total RNA from
C2C12 cells and Xenopus ectodermal explants (animal caps) (see below)
was extracted with the SV Total RNA isolation system kit (Promega) and
TRIzol (Life Technologies), respectively. RNAwas then used to synthesize
cDNA by using a reverse transcription kit [random hexamers and
GoScript (Promega) for C2C12 cell experiments and oligo(dT) and Su-
perScript II reverse transcriptase (Invitrogen) for Xenopus experiments].
mRNA levels were determined by qRT-PCR using either SYBR green/
ROX (GoTaq; Promega) (for C2C12 cells) or iQSYBRGreen Supermix
(Bio-Rad) (for Xenopus animal caps). Primers used to determine gene
expression in C2C12 cells by qRT-PCR were as follows: mouse ZEB1
forward primer 5=-ACCCCTTCAAGAACCGCTTT-3= and reverse
primer 5=-CAATTGGCCACCACTGCTAA-3=, mouse myosin heavy
chain IIa (MyH2) forward primer 5=-CGATGATCTTGCCAGTAATG-3=
and reverse primer 5=-ATAACTGAGATACCAGCG-3= (39), mouse my-
osin heavy chain IIb (MyH4) forward primer 5=-TAAGCACGAGCGCA
GAGTGAAGGAACT-3= and reverse primer 5=-GCTGGATCTTACGGA
ACTTGGCCAGGT-3= (40),mouse troponinT1 (TnnT1) forward primer
5=-GATTCTGTATGAGAGGAAAAAG-3= and reverse primer 5=-TCATA
TTTCTGTTGCTTCAACTT-3= (40), mouse myogenin forward primer
5=-CACTGGAGTTCGGTCCCAA-3= and reverse primer 5=-TGTGGGC
GTCTGTAGGGTC-3= (41), mouse MyoD forward primer 5=-TGGGAT
ATGGAGCTTCTATCGC-3= and reverse primer 5=-GGTGAGTCGAAA
CACGGATCAT-3= (42), mouseMyf-5 forward primer 5=-TCTGGTCCC
GAAAGAACAGC-3= and reverse primer 5=-CTTTTATCTGCAGCACAT
GCATT-3= (43), and mouse glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) forward primer 5=-AACGACCCCTTCATTGAC-3= and re-
verse primer 5=-TCCACGACATACTCAGCAC-3= (44). Primers used for
qRT-PCR of Xenopus animal cap cells were as follows: EF1 forward
primer 5=-CACCATGAAGCCCTTACTGA-3= and reverse primer 5=-AC
CTGTGCGGTAAAAGAACC-3=, TnnI1 (slow skeletal troponin I type 1)
forward primer 5=-CAGTAGCATTCCAGGGCAGT-3= and reverse
primer 5=-TATGTAGCCCCAATGGGAAA-3=, TnnI2 (fast skeletal tro-
ponin I type 2) forward primer 5=-CTCTTCAGCGGGGATATTGA-3=
and reverse primer 5=-ATTTGAGCCCCTCCTTGAGT-3=, MCK forward
primer 5=-ACAAACCAGTGTCCCCTCTG-3= and reverse primer 5=-CC
ACACCAGGAAGGTCTTGT-3=, mActin (muscle actin) forward primer
5=-GCTGACAGAATGCAGAAG-3= and reverse primer 5=-TTGCTTGG
AGGAGTGTGT-3=, and MyoD forward primer 5=-GACCTGCCAATGT
TGTGTTG-3= and reverse primer 5=-CAAAAAGTGGTCCGCAAGTT-
3=. Relative gene expression was calculated by the CT method,
normalizing values relative to either GAPDH (C2C12 cells) or EF1
(Xenopus animal caps) as a reference gene. qRT-PCR data shown are rep-
resentative of at least three independent experiments, with each point
performed in triplicate, and are represented as fold change plus/minus
standard deviation.
Chromatin immunoprecipitation assays. ChIP assays were per-
formed as described previously (38), using an EpiQuick ChIP kit (Epigen-
tek) according to the manufacturer’s instructions. Briefly, C2C12 cells as
either nonconfluent cycling myoblasts or terminally differentiated myo-
tubes were incubated during 20 min with a 1% formaldehyde solution
(ElectronMicroscopy) at room temperature, followed by incubationwith
1.25 M glycine. Upon sonication of cell lysates, chromatin was immuno-
precipitated with the corresponding specific or control antibodies, and
amplification of DNA fragments was assessed by qRT-PCR. Identification
of potential DNA binding sequences for ZEB1/MyoD and design of prim-
ers for qRT-PCR were conducted by using MacVector 12.5 software
(MacVector Inc.). For the ZEB1/MyoD CACCTG site at position1068
of the mouse MyH4 promoter, the primers used to amplify the region
between bp1107 and1014 of this promoter were as follows: forward
primer 5=-TATAAAAGATTTTACCTGCCA-3= and reverse primer 5=-AT
ATTTTCAACCACTGTTCT-3=. For the ZEB/MyoDCAGGTG site at po-
FIG 1 Knockdown of ZEB1 induces earlier protein expression of muscle differentiation genes. C2C12 cells, transfected with either 200 nM specific siRNAs
against ZEB1 (si1ZEB1, si2ZEB1, or si3ZEB1) or a siRNA control (siCtl), were allowed to differentiate for up to 48 h after being switched to differentiation
medium. At the indicated time points, cells were lysed and assessed byWestern blotting for ZEB1 (H-102) and either myogenin (F5D) (A) or MHC (MF-20) (B
to D) along with -tubulin (B5-1-2) as a loading control.
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sition1046 of the mouse skeletal slow troponin T1 (TnnT1) promoter,
the primers used to amplify the region between bp1105 and1020 of
this promoter were as follows: forward primer 5=-TCTCAAACCAAAGC
AAAACCAA-3= and reverse primer 5=-AGTTCCCCGTACCTCATACTC
T-3=. A 191-bp region of themouse GAPDHpromoter, lacking consensus
binding sites for ZEB1/MyoD, was amplified by using forward primer
5=-AGCTACTCGCGGCTTTACG-3= and reverse primer 5=-AAGAAGAT
GCGGCCGTCTCT-3=, modified from those described previously (45).
In all qRT-PCRs, values shown represent relative binding in relation to
input and are the averages of data from two independent ChIP assays,
each performed in triplicate, and representative of at least three experi-
ments.
Transcriptional assays.Transcriptional assays were carried out as de-
scribed previously (38). Briefly, cells were transfected with firefly lucifer-
ase reporter vectors and equal molar amounts of either expression plas-
mids encoding ZEB1 or MyoD or, as controls, the corresponding empty
expression vector. As an internal control for transfection efficiency, 1 g
of SV40–-gal was cotransfected at each point. Total DNA used in each
cotransfection was equalized by adding the promoterless pBluescript SK
vector as required. Firefly luciferase activity was assessed with a Luciferase
Assay System kit (Promega Corporation), whereas -galactosidase activ-
ity was determined with Luminescent -Galactosidase Detection Kit II
(Clontech). Relative luciferase units (RLU) were assessed with aModulus
II Glomax microplate detection system (Promega). RLU values were ex-
pressed as the means of duplicates and are representative of at least four
independent experiments.
Xenopus embryo microinjection and in situ hybridization. Xenopus
laevis embryos were obtained by in vitro fertilization as described previ-
ously (46) and were staged according to methods described previously
(47). Linearized pcDNA3-ZEB1wt, pcDNA3-ZEB1CIDmut, and pSP64T-
MyoD expression vectors were used to produce capped RNA by using the
SP6-Message Machine kit (Ambion). A morpholino oligonucleotide
(MO) against Xenopus ZEB1 (48) (5=-AGATCTGCCAAAGTTGAGCGT
TT-3=) was purchased from Gene Tools LLC. Where indicated, 200 pg of
FIG 2 ZEB1 knockdown induces precocious mRNA expression of several muscle genes. As in Fig. 1, C2C12 cells knocked down for ZEB1 (si1ZEB1) or
transfected with a siRNA control (siCtl) were allowed to differentiate for up to 48 h after being switched to differentiationmedium. At the indicated time points,
mRNA levels for MHC type IIa (MyH2) (A), MHC type IIb (MyH4) (B), troponin T1 (C), myogenin (D), MyoD (E), Myf5 (F), and ZEB1 (G) were determined
by quantitative real-time PCR (qRT-PCR) relative to levels of GAPDH as a reference gene. qRT-PCR was conducted as detailed inMaterials andMethods. Data
shown are a representative case of four independent experiments.
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ZEB1 RNA or 20 ng of ZEB1 MO was injected into one blastomere at the
2-cell stage, along with 20 pg of -galactosidase RNA. Embryos were fur-
ther cultured in 0.2Marc’s modified Ringer’s (MMR) solution contain-
ing 4% Ficoll and 100 g/ml gentamicin. For animal cap isolations, both
cells of pigmented embryos at the 2-cell stage were injected with 100 pg of
MyoD plus either 100 pg ZEB1wt or ZEB1CIDmut mRNA, and embryos
were raised up to the blastula stage (stages 8 to 9). Twenty ectodermal
explants per sample were then isolated and incubated at 25°C in 0.7
MMR supplemented with 1mg/ml bovine serum albumin (BSA) and 100
g/ml gentamicin. For in situ hybridization assays, embryos were grown
to stages 15 to 16, fixed in minimum essential medium with formalde-
hyde, stained with Red-Gal (Research Organics), and processed as de-
scribed previously (49).
Drosophila stocks, crosses, and immunostaining. Full-length cDNA
for zfh-1, obtained from Z. C. Lai (The Pennsylvania State University,
Philadelphia, PA), was inserted into the NotI/XbaI sites of pUAST to
generate independent stocks of upstream activation sequence (UAS)-
zfh-1 flies (genotype, w118; P{wmC 	 UAS-zfh-1.P}2B). UAS-zfh-1-
CIDmut stocks are identical to UAS-zfh-1 stocks, except that the CtBP-
interacting domain (CID) at 790PLDLS796 is mutated to a nonbinding
sequence, 790ASASA796 (genotype, P{wmC 	 UAS-zfh-1-CIDm}2B).
UAS-zfh-1 and UAS-zfh-1-CIDmut stocks are homozygous, viable, and
fertile second-chromosome insertions deposited at the Bloomington
Drosophila Stock Center (Bloomington, IN) under identification num-
bers 6879 and 6880, respectively. zfh-1 expression inUAS-zfh-1 andUAS-
zfh-1-CIDmut was induced by crossing them with 24B-Gal4 or MEF2-
Gal4 stocks obtained as a kind gift from M. Bates (University of
Cambridge, United Kingdom). Embryos were allowed to develop at 25°C
before being examined for expression of different proteins. After standard
fixation, embryos were blocked with 50% normal goat serum in PBS and
incubated with primary and secondary antibodies before the reaction was
developed with a DAB substrate kit (Vector Laboratories), as described
previously (19). Following color development, embryos were mounted in
80% glycerol and examined on a Zeiss Axioplan-2 microscope.
Mouse tissue immunohistochemistry. Mouse tissue samples corre-
sponded to 4-m sections from embryonic day 18.5 (E18.5) C57BL/6J
wild-type (/) and EF1 (ZEB1) null (/) embryos (17). Slides were
subjected to deparaffination and hydration by using standard protocols,
followed by heat-induced antigen retrieval in 10 mM citrate buffer (pH
6.0) for 15 min. Slides were then treated with 0.3% H2O2 in methanol to
block endogenous peroxidase before being incubated with a nonspecific
binding blocking solution (5% normal goat or donkey serum depending
on the host of the secondary antibody, 4% BSA, and 0.5% Tween 20 in
PBS). Next, slides were incubated with the corresponding primary (over-
night at 4°C) and HRP-conjugated (1 h at 37°C) antibodies diluted in
blocking solution. The immunohistochemistry reaction was developed
with the DAB substrate kit (Vector Laboratories), followed by counter-
staining with hematoxylin, before being mounted in di-N-butylphthalate
in xylene solution (DPX; Sigma) for microscopic examination.
RESULTS
Knockdown of ZEB1 induces precocious expression of muscle
differentiation genes. The existence of proteins that bind and
titrate out MyoD, thus preventing MyoD from prematurely acti-
vating its target genes inmyoblasts, is well established (reviewed in
reference 6). Recent evidence indicates that MyoD binding to
DNA is also temporarily delayed through cis-level mechanisms to
control the timing of muscle differentiation (13). In myoblasts,
MyoD is excluded fromG/C-centered E-boxes atmuscle differen-
tiation genes. MyoD only begins to occupy G/C-centered E-boxes
and activate these genes as muscle differentiation progresses (13).
Since ZEB1 is expressed early in development and binds exclu-
sively to G/C-centered E-boxes, we questioned whether its knock-
down in myoblasts would allowMyoD to bind these E-boxes and
trigger a precocious expression of muscle differentiation genes.
To test this hypothesis, we made use of the C2C12 cell myo-
genic conversion model, widely employed in muscle gene expres-
sion studies (20, 50, 51). When grown in high serum (commonly
referred as growth medium [GM]), C2C12 cells maintain a pro-
liferating myoblast-like phenotype, and despite expression of
MyoD, levels of proteins like the intermediate differentiation gene
myogenin or the terminal differentiation markers myosin heavy
chain (MHC) and troponin remain low or absent. Only when
C2C12 cells exit the cell cycle upon reaching confluence and/or are
switched into a low-serum medium (differentiation medium
[DM]) do they fuse and terminally differentiate to formmultinu-
cleated MHC-positive myotubes.
We found here that knockdown of endogenous ZEB1 in
C2C12 cells resulted in precocious expression of differentiation
markers. Upon switching to DM, myogenin protein became de-
tectable earlier in C2C12 cells knocked down for ZEB1 with a
specific siRNA against ZEB1 (si1ZEB1) than in cells transfected
with a siRNA control (siCtl) (Fig. 1A). Upregulation ofMHC also
occurred earlier and reached higher levels in C2C12 cells knocked
down for ZEB1with si1ZEB1 than in siCtl cells (Fig. 1B). A similar
premature expression of MHC occurred when using two addi-
tional and independent siRNAs against ZEB1, here referred to as
si2ZEB1 and si3ZEB1 (Fig. 1C and D).
The earlier induction of muscle genes following ZEB1 knock-
down was also examined at the mRNA level (Fig. 2). Consistent
with the above-described results, mRNA for MHC isoforms IIa
(MyH2) and IIb (MyH4) accumulatedmore rapidly and to higher
levels in ZEB1 knockdown C2C12 cells than in the counterpart
siCtl control cells (Fig. 2A and B). In addition, mRNA expression
FIG 3 ZEB1 knockdown accelerates myotube conversion. (A) C2C12 cells transfected with 200 nM of a specific siRNA against ZEB1 (si1ZEB1) or a siRNA
control (siCtl) were grown to confluence in growth medium (GM) (denoted time zero) before being switched to differentiation medium (DM) and allowed to
differentiate for up to 72 h in DM. At the indicated time points, cells were fixed and immunostained for MHC (MF-20). Nuclei were counterstained with
hematoxylin. Magnification, 4. Captures shown are representative of five independent experiments with si1ZEB1 and siCtl. For all panels, the number of
C2C12 cells throughout the myogenic conversion assay was the same under the ZEB1 knockdown (si1ZEB1, si2ZEB1, and si3ZEB1) and control (siCtl)
conditions, as assessed by trypan blue staining (at the beginning of the assays) and by scoring the number of nuclei counterstained with hematoxylin (at the
different endpoints) (total cell counts are not shown). (B)Quantification of the number of nuclei inMHC-positive cells with respect to the total number of nuclei
in the myogenic conversion experiments shown in panel A. A value of 100 was arbitrarily set for comparison. Counts in panels B to D and F are the averages of
four representative fields. (C) Same as panel B but with si2ZEB1. Similar results were obtained with si3ZEB1 (not shown). (D) Quantification of the number of
MHC-positive myotubes with more than 4 nuclei with respect to the total number of nuclei. Similar results were obtained for si2ZEB1 and si3ZEB1 (data not
shown). (E)Knockdownof ZEB1 also acceleratesmyotube formation inC2C12 cellsmaintained inGM.As for panel A, C2C12 cells were transfectedwith siRNAs
against ZEB1 or the siRNA control, but upon reaching confluence, cells were maintained for the rest of the experiment in GM. Time zero refers to the time point
when cells reached confluence and corresponds to the time point in panels A to D when cells were switched from GM to DM. (F) Quantification of the number
of nuclei in MHC-positive cells with respect to the total number of nuclei in myogenic conversion assays where cells were maintained in GM for the entire
experiment, as described above for panel E.
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FIG 4 ZEB1 binds to G/C-centered E-boxes inmuscle differentiation genes whose transcription is repressed largely through a CtBP-dependentmechanism. (A) ZEB1
andMyoDdisplay differential binding toG/C-centered E-boxes inmuscle differentiation genes inmyoblasts andmyotubes. Shown are data for qRT-PCRof fragments
of the mouse Myh4, troponin T1, and GAPDH promoters immunoprecipitated in ChIP assays from C2C12 myoblasts and myotubes with ZEB1 antibody (E-20X),
MyoD antibody (C-20), or their respective IgG controls. ChIP assays were performed as described in Materials andMethods. Values represent binding relative to the
input averaged from two experiments, each performed in triplicate, and are representative of at least three essays. (B) The basal transcriptional activity of the MHC
promoter is under negative regulation by ZEB1 andCtBP inmyoblasts but not inmyotubes. Nonconfluent cyclingC2C12myoblasts or confluentmyotubes allowed to
terminally differentiate for 48 hwere cotransfectedwith 100nMcontrol siRNA (siCtl) or siRNAs against ZEB1 (si1ZEB1 and si2ZEB1) orCtBP (siCtBP) or equalmolar
amounts of their different combinations along with 0.4 g of a luciferase reporter for the MHC promoter. Transcriptional assays and assessment of relative luciferase
units (RLU) in panels B to E, G, and H were performed as described in Materials and Methods and are representative of at least four independent experiments. The
knockdown efficiencies of si1ZEB1, si2ZEB1, and siCtBP in C2C12 cells are shown in panel F and in Fig. 1A to C. (C) Same as panel B but with 0.2g of the troponin I
promoter as a luciferase reporter. (D) Same as panel B but with 0.2g of theMCK promoter as a luciferase reporter. (E) Same as panel B but with 0.2g of theMyoD
enhancer/promoter. (F) Knockdown efficiency of siRNAs against CtBP and ZEB1 in C2C12 and C3H-10T1/2 cells. (Left) C2C12 cells were transfected with 100 nM
either siCtlor siCtBP.CtBPprotein levelswereassessedbyWesternblottingusinganantibodyagainstCtBP1/2 (E-12)alongwith-tubulin (B5-1-2)as a loadingcontrol.
(Middle)C3H-10T1/2 cells were transfectedwith 200nMeither siCtl or si1ZEB1. ZEB1protein levelswere assessed byWestern blotting using an antibody against ZEB1
(H-102)alongwith-tubulin (B5-1-2)as a loadingcontrol. (Right)Sameas the leftpanelbutwithC3H-10T1/2cells. (G)Musclegenesarealsoundernegative regulation
by ZEB1 andCtBP in theC3H-10T1/2myogenic conversionmodel. C3H-10T1/2 fibroblasts were cotransfectedwith luciferase reporters formuscle gene promoters, as
in panels B to E, plus either 100 nM siRNA control (siCtl) or specific siRNAs against ZEB1 (siZEB1) or CtBP1/2 (siCtBP). The knockdown efficiencies of si1ZEB1 and
siCtBP in C3H-10T1/2 fibroblasts are shown in panel F. (H) Transcriptional repression of muscle genes by ZEB1 depends on CtBP. C3H-10T1/2 fibroblasts were
cotransfected with luciferase reporters for muscle gene promoters as in panel G, 0.6 g of an expression vector for MyoD, and combinations of either 0.4 g of an
expression vector for ZEB1 or equalmolar amounts of its corresponding empty expression vectors plus either 100 nM siRNA control (siCtl) or a specific siRNA against
CtBP1/2 (siCtBP).
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levels of the differentiation genes for troponin and myogenin and
the determination genes for MyoD and Myf-5 also displayed an
earlier induction profile in ZEB1-knocked-down cells than in
controls (Fig. 2C to G). Together, these results indicate that ZEB1
knockdown induces premature induction of muscle genes and
suggest that endogenous ZEB1 may impose a delay on the ability
of MRFs to drive muscle differentiation.
ZEB1 knockdown accelerates myotube formation. Next, we
examined whether this induction of muscle differentiation genes
in C2C12 cells upon ZEB1 knockdown translated into their earlier
terminal differentiation into multinucleated myotubes. Com-
pared to control cells, the formation of myotubes in cells knocked
down for ZEB1 was significantly accelerated, as evidenced mor-
phologically and by quantification of the number of nuclei in
MHC-positive cells with respect to the total number of nuclei (Fig.
3A to C; also data not shown for si3ZEB1). At late time points, the
difference in the number of nuclei inMHC-positive cells between
both experimental conditions was reduced. However, myotube
size (number of nuclei per myotube) was still considerably larger
inZEB1 knockdown cells than in control cells (Fig. 3Ddisplays the
number of MHC-positive myotubes with more than 4 nuclei).
Likewise, although by 72 h, the number of MHC-positive myo-
tubes with more than 4 nuclei was similar under both conditions
(Fig. 3D), ZEB1 knockdown cells still had more nuclei per myo-
tube than control cells (e.g., more myotubes in siZEB1 than in
siCtl exceeded 6 nuclei) (Fig. 3A).
Of note, ZEB1 knockdown also induced accelerated myotube
formation in C2C12 cells that were continuously maintained in
FIG 4 continued
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GM, even after they reached confluence (Fig. 3E and F). This sug-
gests that ZEB1 knockdown can trigger differentiation once cells
have undergone contact-inhibition-mediated cell cycle exit. To-
gether, these results suggest that under normal conditions, endog-
enous ZEB1 delaysmyoblast-to-myotube conversion, while ZEB1
knockdown is sufficient to activate (by relieving repression) a gene
signature associated with terminal muscle differentiation.
Stage-dependent differential binding of ZEB1 and MyoD to
muscle differentiation genes. Formost of its known target genes,
ZEB1 inhibits their expression by binding to G/C-centered
E-boxes at their regulatory regions and actively repressing tran-
scription (14, 15, 24–26, 52, 53).We therefore questionedwhether
the observed changes in muscle gene expression upon ZEB1
knockdown involve binding of ZEB1 to G/C-centered E-boxes in
muscle differentiation genes. As MyoD binds G/C-centered E-
boxes atmuscle differentiation genes inmyotubes but not inmyo-
blasts (13), we also wondered whether ZEB1 could be occupying
these E-boxes at the myoblast stage.
The regulatory regions of muscle terminal differentiation
genes are particularly enriched for G/C-centered E-boxes (12, 13).
We therefore decided to test the ability of ZEB1 andMyoD to bind
to these E-boxes in the promoters of mouse MyH4 and troponin
through chromatin immunoprecipitation (ChIP) assays of C2C12
myoblasts and myotubes (Fig. 4A). In myoblasts, antibodies
against ZEB1, but not its respective control IgG, immunoprecipi-
tated regions of the MyH4 and troponin promoters containing
G/C-centered E-boxes (Fig. 4A). Interestingly,MyoDdid not bind
to the same region of either promoter in myoblasts. Conversely,
when these experiments were performed with myotubes, the re-
verse was observed: MyoD, but not ZEB1, was found to bind to
G/C-centered E-box-containing regions in both promoters
(Fig. 4A). Lastly, both ZEB1 and MyoD antibodies failed to im-
munoprecipitate a fragment of the mouse GAPDH promoter
lacking G/C-centered E-boxes (Fig. 4A). These results indicate
that, in line with our original hypothesis and in an opposite pat-
tern from MyoD, endogenous ZEB1 binds directly to muscle dif-
ferentiation gene promoters in myoblasts but not in myotubes.
Inhibition ofmuscle differentiationbyZEB1 at themyoblast
stage involves CtBP-mediated transcriptional repression.Next,
we explored whether negative regulation ofmuscle differentiation
genes by ZEB1 occurs via transcriptional repression. C2C12 cells
were cotransfected at the myoblast or myotube stage with either
siCtl or specific siRNAs against ZEB1 and luciferase reporters
containing the promoter regions of selectedmuscle genes. Knock-
down of ZEB1 in nonconfluent cycling C2C12myoblasts upregu-
lated the basal transcriptional activity—that is, relieving ZEB1-
mediated repression—of the MHC, troponin, muscle creatine
kinase (MCK), and MyoD gene promoters, the latter to a much
lesser extent (Fig. 4B to E). Interestingly, when the experimentwas
carried out with C2C12 cells that had beenmaintained in DM and
differentiated into myotubes, interference of ZEB1 had no or a
very limited effect (Fig. 4B to E).
ZEB1 represses transcription through recruitment of different
corepressors, some still undetermined, that seem to act in a pro-
moter- and tissue-specific manner (52, 53). A known ZEB1 core-
pressor is CtBP (CtBP1 and CtBP2), a non-DNA-binding protein
that in turn tethers histone-modifying enzymes (33, 54, 55). CtBP
mediates repression of targets of the myogenic MEF2 factor via
recruitment of HDAC9/MITR (56). Here, we used a specific
siRNA against CtBP (siCtBP) (Fig. 4F, left) to investigate a poten-
tial contribution of CtBP to ZEB1-mediated transcriptional inhi-
bition ofmuscle genes.We found that CtBP knockdown inC2C12
myoblasts upregulated, albeit to different degrees, the basal activ-
ity of MHC, MCK, and MyoD promoters (Fig. 4B, D, and E). For
these three promoters, the effect of concomitant knockdown of
CtBP and ZEB1 on C2C12 myoblasts was similar to the effect of
ZEB1 (or CtBP) single knockdown (Fig. 4B, D, and E), suggesting
that CtBP is the main cofactor in the repression of these muscle
genes by ZEB1 at themyoblast stage. Interestingly, relief of repres-
sion of the troponin promoter by CtBP knockdown in C2C12
myoblasts was below the extent of upregulation following knock-
down of ZEB1 (Fig. 4C), indicating that ZEB1-mediated regula-
tion of this gene also involves (and with a greater contribution)
other corepressors (also see below). In contrast, as occurred for
ZEB1 knockdown, interference of CtBP in myotubes had no or
only limited effects on the transcription of all four promoters (Fig.
4B to E).
Active transcriptional repression of muscle genes by ZEB1 and
its dependence on CtBP were then confirmed in C3H-10T1/2 fi-
broblasts, a well-established cell-based model to study transcrip-
tional regulation by MRFs (3–5, 8). Constitutively, C3H-10T1/2
fibroblasts do not express muscle genes, but their transfection
with MyoD is sufficient to induce the formation of myotubes,
although C3H-10T1/2 cells never reached the extent of myogenic
conversion observed for C2C12 cells (3, 4). Here, C3H-10T1/2
cells were cotransfected with MyoD and luciferase reporters for
the four promoters described above, and the expression of ZEB1
was modulated by its overexpression or knockdown. We found
that ZEB1 knockdown in C3H-10T1/2 cells (Fig. 4F, middle) up-
regulated the transcription of all four promoters (Fig. 4G), while
overexpression of ZEB1 inhibited their activity (Fig. 4H).
Knockdown of CtBP in C3H-10T1/2 cells (Fig. 4F, right) aug-
mented the basal activity of these four promoters, including that
of troponin (Fig. 4G). The relief of repression obtained with
siCtBP was similar to or below that observed with interference of
ZEB1 alone. Likewise, elimination of CtBP partially reversed the
repressor effect of ZEB1 on all four promoters albeit to different
levels (Fig. 4H). The differential degree of dependence onCtBP for
the basal endogenous repression of the troponin promoter by
ZEB1 in C2C12 and C3H-10T1/2 cells supports the above-men-
tioned evidence that the identity of ZEB1 corepressors varies in a
promoter- and tissue-specific manner (52). In any case, alto-
gether, these results with cell-based systems indicate that CtBP
mediates a significant share of ZEB1-mediated repression of mus-
cle gene expression.
ZEB1 dependence on CtBP for the regulation of muscle gene
expression was next examined in vivo in Xenopus and Drosophila
embryos. Xenopus embryos were microinjected with MyoD and
either wild-type ZEB1 (ZEB1wt) or a version of ZEB1 where its
CtBP-interacting domain (CID) had beenmutated (ZEB1CIDmut).
At blastula stages, ectodermal explants were isolated from these
embryos, and the effect of both ZEB1 variants onMyoD-mediated
induction of muscle gene expression was examined (Fig. 5A).
ZEB1 inhibited mRNA expression of muscle actin, MCK, slow
skeletal troponin I type 1 (TnnI1), fast skeletal troponin I type 2,
tropomyosin 1 chain, andMyoD.Mutation of the CID region in
ZEB1partially alleviated—and to different degrees—repression of
all the genes examined except for TnnI1, where ZEB1 inhibition
seemed to take place independently of CtBP (Fig. 5A). These re-
sults demonstrate that repression of muscle differentiation genes
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by ZEB1, both in cell-based systems and in vivo, occurs to a large
extent in a CtBP-dependent manner.
The ZEB1 ortholog in Drosophila, zfh-1, is also a transcrip-
tional repressor that binds to G/C-centered E-boxes and interacts
with CtBP (18, 19, 54). Overexpression of zfh-1 in Drosophila
embryos under the control of the heat shock protein 70 promoter
results in amuscle phenotype that includes, but is not limited to, a
downregulation of MHC and MEF2 expression in the somatic
musculature (19). As in any overexpression experiment, these re-
sults cannot rule out that overexpression of zfh-1 is titrating out
other proteins, including CtBP. On the other hand, loss of zfh-1
does not trigger accelerated myogenic differentiation but rather a
complex phenotype with simultaneous loss, gain, and misposi-
tioning of muscle precursors (18), thus suggesting that the role of
zfh-1 during Drosophilamyogenesis is not fully conserved in ver-
tebrate ZEB1. Despite these caveats, we decided to examine
whether the muscle phenotype observed upon zfh-1 overexpres-
sion was dependent on CtBP. zfh-1 is normally downregulated
after gastrulation inmostmesodermal derivatives, includingmus-
cle (57). We used a Gal4-UAS system to maintain the expression
of wild-type zfh-1 (UAS-zfh-1) or a zfh-1 version unable to inter-
act with CtBP (UAS-zfh-1CIDmut) in the developing muscle under
the control of the 24B-Gal4 or MEF2-Gal4 mesoderm-specific
driver lines (Fig. 5B and data not shown for MEF2-Gal4). As de-
scribed previously (19), maintaining zfh-1 expression yielded al-
terations in somatic muscle development and MHC and MEF2
expression that are more complex than just a block in muscle
differentiation (Fig. 5B for 24B-Gal4; also data not shown for
MEF2-Gal4). Nevertheless, the muscle phenotype observed was
dependent on CtBP, as no apparent effect on the embryos crossed
with UAS-zfh-1CIDmut was observed (Fig. 5B for 24B-Gal4; also
data not shown forMEF2-Gal4), even though the zfh-1CIDmut pro-
tein is stably expressed (58). Together, these results demonstrate
that repression ofmuscle differentiation genes byZEB1 (and likely
zfh-1), both in cell-based systems and in in vivomodels, occurs to
a large extent in a CtBP-dependent manner.
Loss of ZEB1 inducesmuscle differentiation gene expression
in vivo. We next sought to confirm whether the induction of
muscle genes upon ZEB1 knockdown observed by cell-based ap-
proaches was recapitulated in vivo. To this end, we examined the
effect of overexpressing and knocking downZEB1duringXenopus
embryonic development. ZEB1 mRNA was coinjected along with
-galactosidase mRNA as a lineage tracer into one of two blasto-
meres at the 2-cell stage. This introduced the injected mRNA into
one bilateral half of the embryo, marked in pink (by staining for
the Red-Gal-galactosidase substrate) and oriented to the right in
Fig. 6A. The contralateral half of the embryo served as a control.
Embryos were then raised to neurula stages, and in situ hybridiza-
tion was used to examine the expression of collagen type II (Col
II), a marker of differentiated mesoderm, and muscle actin, a
musclemarker (Fig. 6A, purple stains).We found that overexpres-
sion of ZEB1 strongly repressed the expression of both markers
(Fig. 6A). Conversely, ZEB1 knockdown by microinjection of a
specific morpholino oligonucleotide (ZEB1 MO) expanded the
expression domains of both markers (Fig. 6A). These results par-
allel our findings in cell-based systems and support a role for ZEB1
in restraining the expression of muscle differentiation genes in
vivo.
Mice carrying a homozygous targeted deletion of ZEB1 die
close to birth with cleft palate and a number of bone and cartilage
abnormalities (17). Although at embryonic days 10 to 11, levels of
MyoD,myogenin, andMCK are not significantly affected in these
mice (17), a molecular analysis of muscle differentiation at later
stages has not been carried out. From the results shownup to here,
one might expect that the temporal pattern of expression of mus-
cle differentiation gene expression would be accelerated in
ZEB1/mouse embryos.
Of all adult MHC isoforms, IIb/MyH4 is induced not only the
FIG 5 In vivo regulation of muscle gene expression by ZEB1/zfh-1 depends on CtBP. (A) Differential requirement for CtBP in ZEB1-mediated repression of
muscle genes in Xenopus ectodermal explants. Xenopus embryos microinjected with mRNA encoding MyoD and either ZEB1wt or ZEB1CIDmut were used to
generate ectodermal explants, and qRT-PCR was used to examine MyoD-induced expression of muscle actin (M.Act), MCK, slow skeletal troponin I type 1
(Tnni1), fast skeletal troponin I type 2 (Tnni2), tropomyosin 1  chain (Tpm1), and MyoD. Isolation of mRNA from ectodermal explants and assessment of
relativemRNA levelswith respect to the reference gene EF1were performed as described inMaterials andMethods.Data shown are a representative case of three
independent experiments. (B) Muscle phenotypes of Drosophila embryos expressing two copies of UAS-zfh-1 or UAS-zfh-1CIDmut under the control of the
24B-Gal4 mesodermal gene as a driver. Embryos were fixed and stained for MEF2 (stage 14) andMHC (stage 16). Note that some myofibers were missing from
muscle groups in UAS-zfh-1 embryos compared to UAS-zfh-1CIDmut embryos.
Inhibition of Muscle Differentiation by ZEB1/CtBP
April 2013 Volume 33 Number 7 mcb.asm.org 1377
 o
n








FIG 6 ZEB1 repressesmuscle gene expression in vivo. (A) ZEB1 regulatesmuscle gene expression inXenopus embryos. In situ hybridization for collagen II (Col II) and
muscle actin (M.Actin)wasperformed inXenopus embryos injectedwithmRNAforZEB1(ZEB1mRNA)or a specificmorpholinooligonucleotide againstZEB1(ZEB1
MO), alongwithmRNAencoding-galactosidase tomark the injected side (oriented rightward), as described inMaterials andMethods. Embryoswere then allowed to
develop up to stages 15 to 16. Percentages of embryos with each phenotype are indicated, with the number of embryos analyzed shown in parentheses. The uninjected
contralateral half of the embryo serves as an internal control (oriented leftward). (B) Muscle differentiation gene expression is accelerated in embryos frommice with
targeted deletion of ZEB1. Shown is immunohistochemistry for MHC IIb (MyH4; BF-F3) in the developing muscle of ZEB1/ and ZEB1/ E18.5 sibling mouse
embryos.MyH4 displayed slightly higher expression levels in ZEB1/ embryos than in the ZEB1/ counterparts.Magnifications of20 and10 are shown. Tissue
immunostainingwasperformedasdescribed inMaterials andMethods. (C)SameaspanelBbutwith immunostaining forMHCisoformIIa (MyH2;SC-71).MyH2was
expressed earlier in ZEB1/ embryos than in the ZEB1/ sibling counterparts, where it was barely detectable. (D) Schematic model of the role of endogenous ZEB1
regulating the temporal pattern of gene expressionduringmuscle differentiation. Inmyoblasts, ZEB1binds toG/C-centeredE-boxes in the regulatory regions ofmuscle
differentiationgeneswhose transcriptionwouldbe repressed at least inpart via recruitmentofCtBP. Inmyotubes,MyoDwoulddisplaceZEB1 fromtheseG/C-centered
E-boxes, thus activating the expression of muscle genes as differentiation progresses.
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earliest (aroundE14.5) but also atmuchhigher levels than the rest,
whilemRNA for isoform IIa/MyH2 starts to be detected only after
E17.5 (59).We decided to examine by immunohistochemistry the
expression of both adult MHC isoforms during late development
in siblingmouse embryos that were either wild type (/) or null
(/) for ZEB1. We found that by E18.5, expression of MyH4
was only slightly higher in ZEB1/ embryos than in the normal
ZEB1/ sibling counterparts (Fig. 6B). Meanwhile, MyH2,
which was barely detectable in ZEB1/ mouse embryos, dis-
played earlier (higher) expression in theZEB1/ sibling counter-
part embryos (Fig. 6C). These results, consistent with the cell-
based and in vivo data described above, indicate that loss of ZEB1
results in an acceleration of the temporal pattern of the muscle
differentiation gene signature.
DISCUSSION
MRFs drive skeletalmyogenesis, but the precise temporal and spa-
tial pattern of muscle development involves regulation of the ex-
pression and activity of MRFs by a wide range of myogenic ago-
nists and inhibitors. Using cell-based systems and several in vivo
models, this study demonstrates that the transcriptional repressor
ZEB1, which binds only to G/C-centered E-boxes, imposes a tem-
porary delay in muscle gene expression and differentiation. ZEB1
knockdown resulted in premature expression of muscle differen-
tiation genes and an acceleration ofmyotube formation. Contrary
to MyoD, ZEB1 binds to G/C-centered E-boxes in muscle differ-
entiation genes at the myoblast stage but not in myotubes. Inhi-
bition of muscle differentiation by ZEB1 involves transcriptional
repression of its targets at the myoblast stage, largely via recruit-
ment of the CtBP corepressor. Finally, we show that the pattern of
gene expression associated with muscle differentiation is acceler-
ated in ZEB1/mouse embryos.
Binding ofMyoD to the regulatory regions ofmuscle genes and
triggering of myogenesis are temporarily blocked in myoblasts by
the action of factors that sequester E-proteins and/or MyoD itself
or that bind to the same E-box sequences (1, 6). Accordingly,
exogenous overexpression of either type of factor (squelching or
E-box binding factors) can inhibit MyoD-induced myotube for-
mation in fibroblasts (7–9, 11, 13, 26, 60). However, in addition to
the caveat of overexpression experiments mentioned above, dis-
placement of MyoD from E-boxes when these inhibitory factors
are overexpressed occurs independently of their DNA binding af-
finity relative to MyoD. Recently, it was shown that induction of
myogenesis by MyoD is also regulated by its affinity for G/C-
centered E-boxes with respect to other endogenous E-box binding
proteins like Snail factors (13).
FIG 6 continued
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In myoblasts, MyoD binds to A/T-centered E-boxes but not to
G/C-centered E-boxes, which are predominant in muscle differ-
entiation genes and can be bound by Snail factors. It is only as
differentiation progresses that MyoD occupies these E-boxes and
activates muscle differentiation (13). ZEB1 binds G/C-centered
E-boxes (mostly of the CACCTG/CAGGTG type also preferred by
MyoD) in the promoters of a wide range of genes, where it can act
in competition with other bHLH and zinc finger factors (24–28).
Upon binding to these E-boxes, ZEB1 regulates gene expression
mostly by active transcriptional repression (26, 52–54). Here, we
found that knockdown of endogenous ZEB1 in nonconfluent cy-
cling myoblasts, but not in differentiated myotubes, upregulates
the basal transcriptional activity of several muscle gene promot-
ers. This result suggests that these genes are normally under neg-
ative regulation by ZEB1 at the myoblast stage but not in myo-
tubes (Fig. 6D).
Interestingly, ZEB1 is a downstream target of both Snail1 and
Snail2 (21–23). Snail1/2 and ZEB1 have been extensively charac-
terized for their role as inducers of an epithelial-to-mesenchymal
transition (EMT) in the context of cancer cell invasion and tumor
metastasis (14, 15). In triggering an EMT at the invasive front of
carcinomas, both Snail1 and ZEB1 repress an overlapping set of
epithelial specification markers, but they participate at different
stages, with Snail1 triggering the EMT process and ZEB1 main-
taining it (21, 22, 32). Cells in the dermomyotome also undergo an
EMT to delaminate and migrate into the primary myotome (1).
Conceivably, a similar temporal division of labor between Snail1
and ZEB1 could occur during muscle differentiation, as evidence
already exists that Snail1 triggers an EMT in the dermomyotome
and regulates its timing (61).
Transcriptional repression by ZEB1 is mediated by the tether-
ing of different corepressors whose identity seems to vary in a
tissue- and promoter-specific manner (reviewed in reference 52).
Thus, repression of CD4 in lymphocytes is dependent on recruit-
ment of the Tip60 histone acetyltransferase, while CtBP mediates
ZEB1 repression of the growth hormone gene in the pituitary
gland or interleukin-2 and Bcl-6 in lymphocytes. In heterologous
Gal4/LexA reporter systems, ZEB1 antagonizes transcriptional ac-
tivation by most transcription factors tested, including that in-
duced by the myogenic factor MEF2C (53). ZEB1 repression of
MEF2-mediated transcription involves the central region of
ZEB1, encompassing the interacting domain forCtBP (33, 53, 54).
In the context of muscle gene expression, CtBP is known to me-
diate repression ofMEF2 targets by recruitment ofHDAC9/MITR
(56). Our results for cell-based systems and in vivo models dem-
onstrated that CtBP participates in ZEB1 repression of muscle
genes although to different degrees, being dispensable for the reg-
ulation of TnnI1 in Xenopus but largely required in the case of
MyoD in C3H-10T1/2 fibroblasts. Similarly, the small depen-
dence on CtBP for the repression of troponin in C2C12 cells rel-
ative to C3H-10T1/2 fibroblasts corroborated the promoter and
tissue specificity of the cofactors involved in ZEB1-mediated re-
pression. Nevertheless, while CtBP accounts for a large share of
ZEB1 repression of muscle differentiation genes, our data also
indicate that their inhibition by ZEB1 implicates additional CtBP-
independent mechanisms that remain to be elucidated. In line
with this, repression of E-cadherin by ZEB1 requires the summa-
tive action of several cofactors (62).
MyoD function, rather than its expression, is temporarily
blocked in myoblasts (6). Likewise, ZEB1’s antimyogenic activity
seems to also be regulated during muscle differentiation. Thus,
ZEB1 is expressed in the epitheliumof the undifferentiated somite
and the dermomyotome and continues to be expressed as muscle
starts to form (16, 17). The required functional inactivation of
ZEB1 during muscle differentiation may take place through sev-
eralmechanisms, but our results here indicate that, at least in part,
this might occur via displacement of ZEB1 from G/C-centered
E-boxes byMyoD asmuscle differentiation progresses. In keeping
with this model, ZEB1 is also in equilibrium with the bHLH E2A
protein for binding to the immunoglobulin heavy chain enhancer
during B-cell differentiation (24).
In summary, this work has shown that muscle differentiation
genes are under transcriptional repression by ZEB1/CtBP inmyo-
blasts. ZEB1 imposes a temporal delay in muscle differentiation,
and its regulatory and functional interplay with MyoD appears to
play an essential role in controlling the temporal pattern of gene
expression during muscle differentiation.
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